finanzen.net

Das könnte abgehen....

Seite 2 von 44
neuester Beitrag: 16.10.15 02:19
eröffnet am: 30.01.09 11:58 von: Touwse Anzahl Beiträge: 1095
neuester Beitrag: 16.10.15 02:19 von: Heron Leser gesamt: 88574
davon Heute: 4
bewertet mit 9 Sternen

Seite: 1 |
| 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | 44   

25.01.10 20:12

588 Postings, 3503 Tage iBrokerKeryx, AEterna say cancer drug met study goals


Keryx and AEterna Zentaris say perifosine improved survival compared to potential competitor.

On Monday January

... (automatisch gekürzt) ...

http://finance.yahoo.com/news/...y-cancer-drug-apf-357406049.html?x=0
Moderation
Moderator: lassmichrein
Zeitpunkt: 03.02.10 17:16
Aktion: Kürzung des Beitrages
Kommentar: Urheberrechtsverletzung, bitte nur zitieren

 

 

25.01.10 21:59

588 Postings, 3503 Tage iBrokerEine interessante Zusammenfassung...


...über heutiges Ergebnis.

January 25th, 2010

Keryx?s Perifosine, Slam Dunk Data Leaves

... (automatisch gekürzt) ...

http://www.gekkowire.com/?p=2265
Moderation
Moderator: lassmichrein
Zeitpunkt: 03.02.10 17:17
Aktion: Kürzung des Beitrages
Kommentar: Urheberrechtsverletzung, bitte nur zitieren

 

 

26.01.10 16:34

1017 Postings, 3622 Tage dailytradewie gehts hier weiter?

akte gibt wieder nach. sollte sie nicht nach oben gehen nach solch guten news  

26.01.10 19:08

588 Postings, 3503 Tage iBrokervolumen

gestern hatten wir schöne volumen...  heute etwas verhalten (siehe chart)

                       FRA                    Nasdaq
25.01.2010     2,15 / 3.266      2,84 / 7.242.452  
22.01.2010     2,08 / 7.616      2,74 / 962.261  
21.01.2010     2,00 / 500         2,77 / 1.447.270  
20.01.2010     1,91 / 0             2,86 / 1.371.858  
19.01.2010     1,85 / 0             2,80 / 1.114.720  
Angehängte Grafik:
20100126.png (verkleinert auf 67%) vergrößern
20100126.png

27.01.10 18:24
1

4951 Postings, 4336 Tage 0815axDrug Shows Promise in Late-Stage Colon Cancer Pati

Keryx / Aeterna Drug Shows Promise in Late-Stage Colon Cancer Patients
   
Written by Mike Havrilla      
Wednesday, 27 January 2010 06:34
http://biomedreports.com/articles/most-popular/...ancer-patients.html

 

-----------
*amM - keine Kaufempfehlung

http://www.rot-weiss-erfurt.de/

28.01.10 12:54

1017 Postings, 3622 Tage dailytradeheute gibts ne pressekonferenz

mal sehen was sie zu den neuen phase 3 durchläufen sagen werden  

29.01.10 14:52

1017 Postings, 3622 Tage dailytradewieder gute news heute

29.01.10 19:57

1017 Postings, 3622 Tage dailytradeund trotzdem gehts wieder bergab

das ist doch nicht normal oder  

03.02.10 17:14

1017 Postings, 3622 Tage dailytradewieder gute news heute

wieder gehts runter.
unglaublich  

05.02.10 17:50

1017 Postings, 3622 Tage dailytradewas tun

05.02.10 21:49
1

21531 Postings, 3986 Tage HeronBioMedsReport 05.02.2010

Quelle: BioMedsReport.com

Keryx Biopharmaceuticals (Nasdaq: KERX) reagiert auf fehlerhafte Bericht über geplante Phase-III-Studie bei Patienten mit kolorektalem Karzinom

http://translate.google.de/...orectal-cancer.html&sl=en&tl=de  

05.02.10 21:55

1017 Postings, 3622 Tage dailytradeinformativ, danke!

und zugleich beruhigend
schönes we  

09.02.10 18:49
1

4951 Postings, 4336 Tage 0815axWebcast Presentation Feb. 9, 2010 2:00 p.m. ET

Title: Keryx Biopharmaceuticals, Inc. at Biotechnology Industry Organization CEO & Investor Conference

Date and Time: Tuesday, February 9, 2010 2:00 p.m. ET  
 Duration:§1 Hour
 Location:§New York, NY

Webcast Presentation
http://www.veracast.com/webcasts/bio/ceoinvestor2010/65210174.cfm
-----------
*amM - keine Kaufempfehlung

http://www.rot-weiss-erfurt.de/

09.02.10 18:52

4951 Postings, 4336 Tage 0815axi

-----------
*amM - keine Kaufempfehlung

http://www.rot-weiss-erfurt.de/

09.02.10 19:24

1017 Postings, 3622 Tage dailytradedanke für die info

vielleicht gibts was gutes....der chart sieht nicht besonders aus...  

11.02.10 18:53

1017 Postings, 3622 Tage dailytradekonsolidierung vielleicht schon beendet

12.02.10 17:07

1017 Postings, 3622 Tage dailytradewenn die 2,55 dollar fallen könnte es richtig rauf

gehen.
da ist jedoch ein widerstand.
schau mer mal  

12.02.10 19:04

1017 Postings, 3622 Tage dailytradeKeryx Artikel

Dream Stocks for Biotech Investors
By Dave Mock
February 12, 2010 | Comments (0)

Recs
1

Email
 Share
Print
TRUE
Centrue Financia
Rate TRUE
CAPS Rating 0/5 Stars
$2.65 $-0.10 (-3.64%)

Disney Buys Marvel!

David Gardner called it. He?s up 1,334%! See what David?s recommending that you buy NEXT.
Click Here Now
Investors are always hunting for the next big stock -- the dream stock whose price increases several times over when the market finally discovers it. It's easy to look back and discover the 10 best stocks of the past decade. But I'm more interested in the tools that can help me evaluate tomorrow's greatest companies.

Motley Fool CAPS offers a variety of resources to aid Fools in finding tomorrow's leaders. Our 150,000-member community is full of investors helping each other beat the market.

We'll enlist CAPS to screen for biotech companies, then get the story behind some of its more highly rated stocks. CAPS' nifty screener will help us find stocks with:

A market cap of at least $100 million.
A three-year revenue growth rate of at least 30%.
A price-to-earnings ratio of less than 25.
Then we'll tap the collective intelligence of our CAPS members to see whether these companies present real opportunities -- or whether the numbers fail to tell the true story.

Opinions with the numbers
Here are some of the more interesting stocks our screen returned.

Company
Revenue Growth Rate,
Past 3 Years
CAPS Rating
(out of 5)
Keryx Biopharmaceuticals (Nasdaq: KERX)
158.5%
***
VIVUS (Nasdaq: VVUS)
64.6%
***
Biogen Idec (Nasdaq: BIIB)
35.6%
***
Data and star rankings from CAPS as of Feb. 11.
Keryx Biopharmaceuticals
Keryx has shown good progress with its drug candidates in clinical trials recently, especially the news that its colon cancer drug, perifosine, showed a more than 60% improvement in overall survival in midstage trials. The company looks to begin late-stage trials in the second quarter, and is also working on other treatments for the drug that show promise. Top all this off with other expected late-stage trials for its kidney drug, Zerenex, and it's no wonder a solid following of CAPS investors see potentially brighter days ahead for the company.

At this point, about 91% of the 209 CAPS members rating Keryx Biopharmaceuticals see it outperforming the broader market.  

18.02.10 18:29

1017 Postings, 3622 Tage dailytradewie gehts weiter

wann kommen neue news
weiss jemand etwas?  

25.02.10 17:45

1017 Postings, 3622 Tage dailytradekein schlechtes Kursziel: 7 Dollar

Keryx Biopharmaceuticals initiated with a Buy at Roth Capital
Target $7. :theflyonthewall.com

25.02.2010  

01.03.10 19:24

1017 Postings, 3622 Tage dailytradenews von gestern nochmal:

March 1, 2010 7:42 AM EST
Aterna Zentaris Inc. (NASDAQ: AEZS) has received a positive opinion for orphan medicinal product designation for its compound perifosine from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency, for the treatment of multiple myeloma. Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), Aterna Zentaris' partner and licensee for perifosine in the North American market, already announced in September 2009 that it has received Orphan Drug Designation for perifosine for the treatment of multiple myeloma from the U.S. Food and Drug Administration (FDA).

Orphan medicinal product designation is granted by the European Commission, following a positive opinion from the COMP, to a medicinal product that is intended for the diagnosis, prevention or treatment of a life-threatening or a chronically debilitating condition affecting not more than five in 10,000 persons in the Community when the application for designation is submitted.  

01.03.10 21:41

1017 Postings, 3622 Tage dailytradeempfehlung

Keryx Biopharmaceuticals initiated with an Outperform at Rodman & Renshaw
Target $6. :theflyonthewall.co  

Seite: 1 |
| 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | 44   
   Antwort einfügen - nach oben

Online Brokerage über finanzen.net

finanzen.net Brokerage
Handeln Sie für nur 5 Euro Orderprovision* pro Trade aus der Informationswelt von finanzen.net!

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln
Kontakt - Impressum - Werben - Pressemehr anzeigen
Top News
Beliebte Suchen
DAX 30
Öl
Euro US-Dollar
Bitcoin
Goldpreis
Meistgesucht
MTU Aero Engines AG Em 2017A2G83P
Braas Monier Building Group S.A.BMSA01
Microsoft Corp.870747
Deutsche Bank AG514000
Daimler AG710000
Scout24 AGA12DM8
Apple Inc.865985
Amazon906866
Wirecard AG747206
Allianz840400
BMW AG519000
TeslaA1CX3T
E.ON SEENAG99
CommerzbankCBK100
BASFBASF11